From Atherosclerosis to Acute Coronary Syndromes: The Role of Soluble CD40 Ligand

Trends in Cardiovascular Medicine

Volumn 20, Issue 5, 2010, Pages 153-164

  Tousoulis, Dimitris ^a   Androulakis, Emmanouel ^a   Papageorgiou, Nikolaos ^a   Briasoulis, Alexandros ^a   Siasos, Gerasimos ^a   Antoniades, Charalambos ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CD40 ANTIGEN; CD40 LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTIGEN BINDING; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CD40 LIGAND; HUMANS;

EID: 79960098236     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2010.12.004     Document Type: Review

References (94)

1. Aarsetøy H., Brügger-Andersen T., Hetland Ø., et al. Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand; pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. Thromb Haemost 2006, 95:329-336.
2. Aggarwal A., Schneider D.J., Terrien E.F., et al. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 2004, 93:6-9.
3. Anand S.X., Viles-Gonzalez J.F., Badimon J.J., et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003, 90:377-384.
4. Andre P., Prasad K.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a b3 integrin-dependent mechanism. Nat Med 2002, 8:247-252.
5. Andreou I., Tousoulis D., Miliou A., et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 2010, 210:194-198.
6. Antoniades C., Tousoulis D., Vasiliadou C., et al. Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: effects on the release of sCD40L during the acute phase of premature myocardial infarction. J Am Coll Cardiol 2006, 47:1959-1966.
7. Antoniades C., Van-Assche T., Shirodaria C. Preoperative sCD40L levels predict risk of atrial fibrillation after off-pump coronary artery bypass graft surgery. Circulation 2009, 120:S170-S176.
8. Apple F.S., Smith S.W., Pearce L.A., Murakami M.M. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2009, 55:93-100.
9. Aukrust P., Müller F., Ueland T. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999, 100:614-620.
10. Aukrust P., Yndestad A., Smith C., et al. Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. Expert Opin Pharmacother 2005, 6:2169-2180.
11. Azar R.R., Kassab R., Zoghbi A., et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006, 151:521.e1-521.e4.
12. Blake G.J., Ostfeld R.J., Yucel E.K. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003, 23:e11-e14.
13. Bleie Ø., Semb A.G., Grundt H., et al. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med 2007, 262:244-253.
14. Brili S., Tousoulis D., Antoniades C., et al. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. J Am Coll Cardiol 2008, 51:742-749.
15. Burdon K.P., Langefeld C.D., Beck S.R., et al. Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS). Am Heart J 2006, 151:706-711.
16. Chan F.K., Chun H.J., Zheng L., et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
17. Chatzigeorgiou A., Lyberi M., Chatzilymperis G., et al. CD40/CD40L signaling and its implication in health and disease. Biofactors 2009, 35:474-483.
18. Chen C., Chai H., Wang X. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008, 112:3205-3216.
19. Ciaccio M., Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol 2010, 5:30-36.
20. De Lemos J.A., Zirlik A., Schönbeck U. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2192-2196.
21. Dominguez-Rodriguez A., Abreu-Gonzalez P., Avanzas P., et al. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-effects on soluble CD40 ligand concentrations. Atherosclerosis 2009, 206:523-527.
22. D'Orlando O., Gri G., Cattaruzzi G. Outside inside signalling I CD40-mediated B cell activation. J Biol Regul Homeost Agents 2007, 21:49-62.
23. Erbel C., Sato K., Meyer F.B., et al. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol 2007, 102:123-132.
24. Foo R.S. Present-day investigations cannot adequately determine the risk of acute coronary syndromes. Clin Lab 2001, 47:257-263.
25. Furman M.I., Krueger L.A., Linden M.D., et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004, 43:2326-2328.
26. Furman M.I., Krueger L.A., Linden M.D., et al. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 2005, 3:312-320.
27. Garlichs C.D., Eskafi S., Raaz D. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001, 86:649-655.
28. Grafe M., Dietrich T., Stibenz D., et al. CD40 targeted imaging of atherosclerotic plaque lesions in ApoE -/- mice. Circulation 2008, 118:S554.
29. Grafe M., Dietrich T., Stibenz D., et al. Imaging of atherosclerotic lesions in ApoE -/- mice by targeting of CD40. Circulation 2009, 120:S1030-S1031.
30. Heeschen C., Dimmeler S., Hamm C.W. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104-1111.
31. Hejase de Trad C. Soluble CD40L versus myocyte enhancer factor: predicting a prominent marker for cardiovascular disease. Conf Proc IEEE Eng Med Biol Soc 2006, 1:1698-1701.
32. Henn V., Slupsky J.R., Gräfe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
33. Hollenbaugh D., Mischel-Petty N., Edwards C.P. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995, 182:33-40.
34. Hoshiga M., Arishiro K., Nakakoji T., et al. Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease. J Atheroscler Thromb 2010, 17:705-711.
35. Hoskins M.H., Leleiko R.M., Ramos J.J., et al. Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use. J Cardiovasc Pharmacol Ther 2010, 15:47-52.
36. Husted S., Storey R.F., Harrington R.A., et al. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010, 33:206-212.
37. Jacobson E.M., Concepcion E., Oashi T., Tomer Y. A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 2005, 146:2684-2691.
38. Kinlay S., Schwartz G.G., Olsson A.G., et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004, 110:386-391.
39. Klohs J., Gräfe M., Graf K., et al. In vivo imaging of the inflammatory receptor CD40 after cerebral ischemia using a fluorescent antibody. Stroke 2008, 39:2845-2852.
40. L'Allier P.L., Tardif J.C., Grégoire J. Sustained elevation of serum CD40 ligand levels one month after coronary angioplasty predicts angiographic restenosis. Can J Cardiol 2005, 21:495-500.
41. Leroyer A.S., Rautou P.E., Silvestre J.S., et al. CD40 ligand microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol 2008, 52:1302-1311.
42. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003, 169:203-214.
43. Lutgens E., Gorelik L., Daemen M.J., et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999, 5:1313-1316.
44. Lutgens E., Lievens D., Beckers L., et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010, 207:391-404.
45. Mach F., Schönbeck U., Sukhova G.K., et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394:200-203.
46. Mälarstig A., Lindahl B., Wallentin L., Siegbahn A. Soluble CD40L levels are regulated by the -3459 A > G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol 2006, 26:1667-1673.
47. Martín-Ventura J.L., Blanco-Colio L.M., Tuñón J., et al. Biomarkers in cardiovascular medicine. Rev Esp Cardiol 2009, 62:677-688.
48. Marx N., Imhof A., Froehlich J., et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003, 107:1954-1957.
49. Miller D.L., Yaron R., Yellin M.J. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J. Leukoc Biol 1998, 63:373-379.
50. Mitsios J.V., Papathanasiou A.I., Rodis F.I., et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004, 109:1335-1338.
51. Montalescot G., Drexler H., Gallo R., et al. Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized; double-blind ARCHIPELAGO study. Eur Heart J 2009, 30:2733-2741.
52. Morrow D.A., Sabatine M.S., Brennan M.L. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008, 29:1096-1102.
53. Nannizzi-Alaimo L., Alves V.L., Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003, 107:1123-1128.
54. Obradovic S.D., Antovic J.P., Antonijevic N.M., et al. Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention. Blood Coagul Fibrinolysis 2009, 20:283-289.
55. Olenchock B.A., Wiviott S.D., Murphy S.A. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis 2008, 26:79-84.
56. Pajukanta P., Cargill M., Viitanen L., et al. Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland. Am J Hum Genet 2000, 67:1481-1493.
57. Papageorgiou N., Tousoulis D., Antoniades C. The impact of statin administration in acute coronary syndromes. Hellenic J Cardiol 2010, 51:250-261.
58. Pastuszczak M., Kotlarz A., Mostowik M., et al. Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thromb Res 2010, 125:382-386.
59. Prasad K.S., Andre P., He M., et al. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A 2003, 100:12367-12371.
60. Prontera C., Martelli N., Evangelista V. Homocysteine modulates the CD40/CD40L system. J Am Coll Cardiol 2007, 49:2182-2190.
61. Ray M.J., Juneja M., Bett N., Walters D.L. A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. EuroIntervention 2009, 5:330-335.
62. Rizvi M., Pathak D., Freedman J.E., Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 2008, 14:530-538.
63. Rondina M.T., Lappé J.M., Carlquist J.F. Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology 2008, 109:196-201.
64. Santilli F., Basili S., Ferroni P., Davì G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007, 2:256-268.
65. Schönbeck U., Libby P. CD40 signaling and plaque instability. Circ Res 2001, 89:1092-1103.
66. Schönbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58:4-43.
67. Schönbeck U., Sukhova G.K., Shimizu K., et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 2000, 97:7458-7463.
68. Serebruany V.L., Kogushi M., Dastros-Pitei D., et al. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist; on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009, 102:111-119.
69. Smook M.L., Heeringa P., Damoiseaux J.G., et al. Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis 2005, 183:275-282.
70. Stefanadi E., Tousoulis D., Androulakis E.S., et al. Inflammatory markers in essential hypertension: potential clinical implications. Curr Vasc Pharmacol 2010, 8:509-516.
71. Tan J., Hua Q., Gao J., Fan Z.X. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008, 31:413-418.
72. Tian C., Qin W., Li L., et al. A common polymorphism in CD40 Kozak sequence (-1C/T) is associated with acute coronary syndrome. Biomed Pharmacother 2010, 64:191-194.
73. Tousoulis D., Antoniades C., Koumallos N., Stefanadis C. Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev 2006, 17:225-233.
74. Tousoulis D., Antoniades C., Nikolopoulou A. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 2007, 37:623-628.
75. Tousoulis D., Antoniades C., Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007, 93:1001-1007.
76. Tousoulis D., Briasoulis A., Dhamrait S.S., et al. Effective platelet inhibition by aspirin and clopidogrel: where are we now?. Heart 2009, 95:850-858.
77. Tousoulis D., Charakida M., Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006, 92:441-444.
78. Tousoulis D., Kampoli A.M., Stefanadi E. New biochemical markers in acute coronary syndromes. Curr Med Chem 2008, 15:1288-1296.
79. Tousoulis D., Paroutoglou I.P., Papageorgiou N., et al. Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacol Ther 2010, 127:108-120.
80. Undas A., Szułdrzyński K., Brummel-Ziedins K.E., et al. Systemic blood coagulation activation in acute coronary syndromes. Blood 2009, 113:2070-2078.
81. Varo N., De Lemos J.A., Libby P. Soluble CD40L risk prediction after acute coronary syndromes. Circulation 2003, 108:1049-1052.
82. Vaulin N.A., Pokrovskaia E.V., Deev A.D., Gratsianskiǐ N.A. Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor. Kardiologiia 2006, 46:37-42.
83. Vavuranakis M., Latsios G., Aggelis D., et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther 2006, 28:860-871.
84. Vishnevetsky D., Kiyanista V.A., Gandhi P.J. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother 2004, 38:1500-1508.
85. Walters D.L., Ray M.J., Wood P., et al. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention. Eur J Clin Invest 2010, 40:139-147.
86. Wang C., Yan J., Yang P., et al. The Relationship between CD40 gene polymorphism and unstable coronary atherosclerotic plaques. Clin Cardiol 2010, 33:E55-E60.
87. Wang Y., Li L., Tan H.W. Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart disease. Clin Cardiol 2007, 30:86-91.
88. Wöhrle J., Nusser T., Merkle N., et al. Myocardial perfusion reserve in cardiovascular magnetic resonance: correlation to coronary microvascular dysfunction. J Cardiovasc Magn Reson 2006, 8:781-787.
89. Xu Y., Song G. The role of CD40-CD154 interaction in cell immunoregulation. J Biomed Sci 2004, 11:426-438.
90. Yan J., Wang C., Du R., et al. Association analysis of CD40 gene polymorphism with acute coronary syndrome. Clin Exp Med 2010, 10:253-258.
91. Yan J., Wu Z., Huang Z., et al. Clinical implications of increased expression of CD40L in patients with acute coronary syndromes. Chin Med J (Engl) 2002, 115:491-493.
92. Yan J.C., Wu Z.G., Kong X.T., et al. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome. Acta Pharmacol Sin 2004, 25:251-256.
93. Yan J.C., Zhu J., Gao L., et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes. Clin Chim Acta 2004, 343:155-159.
94. Zirlik A., Maier C., Gerdes N., et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007, 115:1571-1580.